Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up
(RTTNews) - Tuesday, Prelude Therapeutics Incorporated (PRLD) announced a clinical trial collaboration with Eli Lilly (LLY) to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast cancer.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.